Enlivex is an Israeli-based development-stage biopharmaceutical company that focuses on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that rebalances the immune system using its natural regulation mechanisms to treat life-threatening unbalanced immune systems. Enlivex aims to reshape the way immune, autoimmune, and inflammatory conditions are both thought of and treated by using the body's native mechanisms to restore immune balance. The company has an advanced clinical-stage pipeline with promising Phase II results and has multi-billion-dollar markets in post-BMT complications, sepsis, and solid tumors.